EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Dorothy Cheuk-Yan Yiu, Jimmy Che-To Lai iD, Landon Long Chan iD, Grace Lai-Hung Wong iD, Mandy Sze-Man Lai, Vincent Wai-Sun Wong iD, Yee-Kit Tse, Henry Lik-Yuen Chan iD, Stephen Lam Chan iD, Terry Cheuk-Fung Yip iD

Alimentary Pharmacology & Therapeutics · 2026-02 · 63 (3) · 383-395

DOI: 10.1111/apt.70367 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 05.09.2025. Verfasst von Dorothy Cheuk-Yan Yiu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Protein Kinase Inhibitors, Liver Neoplasms, Hepatitis B virus. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Current and past hepatitis B virus (HBV) infection remains the leading cause of liver cancer in endemic areas.

Aim

To examine the risk of HBV reactivation (HBVr) in patients receiving immune checkpoint inhibitors (ICI) for liver cancer.

Methods

Patients with current or past HBV infection receiving systemic treatments for liver cancer from March 2015 to March 2023 were identified using a territory‐wide electronic database in Hong Kong. The primary outcome was HBVr in ICI compared to tyrosine kinase inhibitor (TKI) use, defined according to the American Association for the Study of Liver Diseases criteria. The secondary outcome was HBVr in different types of ICI.

Results

One thousand five hundred and ninty‐six patients with current or past HBV infection (222 first received ICI; 1374 first received TKI) were included. 205 patients (12.8%) had past HBV infection, and 93.2% of the cohort were on HBV antiviral prophylaxis at baseline. At a median of 10.7 months (IQR: 3.7–12.0), 25 (1.6%) patients had HBVr, among whom 5 were exposed to ICI. The 12‐month cumulative incidence (95% CI) of HBVr of the 1596 patients was 1.7% (1.1%–2.4%). The proportion of patients experiencing HBVr with and without antiviral prophylaxis was 1.4% and 3.7%, respectively. In multivariable analysis, ICI use was not associated with a higher risk of HBVr than TKI use, and the use of different ICI did not impact the risk of HBVr.

Conclusion

With adequate antiviral prophylaxis, the absolute risk of HBVr is low in advanced HBV‐related liver cancer patients receiving ICI, regardless of current or past HBV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsProtein Kinase InhibitorsLiver NeoplasmsHepatitis B virusVirus ActivationHepatitis BHumansMaleFemaleMiddle AgedAgedHong KongRetrospective StudiesAntiviral AgentsRisk FactorsTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

hepatitis B reactivationhepatocellular carcinomaimmune checkpoint inhibitortyrosine kinase inhibitor

Substanzen

Immune Checkpoint InhibitorsProtein Kinase InhibitorsAntiviral AgentsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
  • Medical Data Analytics Centre (MDAC), The Chinese University of Hong Kong, Hong Kong, Hong Kong.
  • Institute of Digestive Disease, Hong Kong, Hong Kong.
  • Faculty of Medicine, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
  • State Key Laboratory of Translational Oncology, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
  • Department of Internal Medicine, Union Hospital, Hong Kong, Hong Kong.

ORCID-Profile: Jimmy Che-To Lai, Landon Long Chan, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Henry Lik-Yuen Chan, Stephen Lam Chan, Terry Cheuk-Fung Yip

Zitieren

APA

Yiu, D. C., Lai, J. C., Chan, L. L., Wong, G. L., Lai, M. S., Wong, V. W., Tse, Y. K., Chan, H. L., Chan, S. L., & Yip, T. C. (2026). Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer. Alimentary Pharmacology & Therapeutics, 63(3), 383-395. https://doi.org/10.1111/apt.70367

Vancouver

Yiu DC, Lai JC, Chan LL, Wong GL, Lai MS, Wong VW, et al. Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer. Alimentary Pharmacology & Therapeutics. 2026;63(3):383-395. doi:10.1111/apt.70367

BibTeX
@article{Yiu2026,
  author = {Yiu, Dorothy Cheuk-Yan and Lai, Jimmy Che-To and Chan, Landon Long and Wong, Grace Lai-Hung and Lai, Mandy Sze-Man and Wong, Vincent Wai-Sun and Tse, Yee-Kit and Chan, Henry Lik-Yuen and Chan, Stephen Lam and Yip, Terry Cheuk-Fung},
  title = {Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {63},
  number = {3},
  pages = {383--395},
  doi = {10.1111/apt.70367}
}
Kostenlos starten →